Business Context and Reporting Period
Company: Passage BIO, Inc. (Nasdaq: PASG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Passage BIO is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, is a gene replacement therapy targeting progranulin deficiency in Frontotemporal Dementia (FTD-GRN). The company has no approved products and has not generated revenue from commercial product sales.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Net Loss | $(64,767) | $(102,062) |
| Research & Development Expenses | $40,179 | $61,419 |
| General & Administrative Expenses | $24,988 | $41,580 |
| Impairment of Long-Lived Assets | $5,233 | $5,390 |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2024) | $76,800 | $114,294 |
| Accumulated Deficit (Dec 31, 2024) | $(659,235) | $(594,468) |
| Net Cash Used in Operating Activities | $(47,956) | $(78,264) |
Note: The company reported $8.2 million in non-refundable sublicense and transition services payments received from Gemma Biotherapeutics, Inc., recorded as a liability as revenue recognition criteria were not yet met.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by approximately $37.3 million (36%) compared to 2023. This was driven by a $21.2 million decrease in R&D expenses and a $16.6 million decrease in G&A expenses.
- Portfolio Restructuring: In July 2024, the company out-licensed three pediatric programs (GM1, Krabbe, and MLD) to Gemma Biotherapeutics. This eliminated future funding commitments to the University of Pennsylvania for discovery research and reduced third-party clinical and manufacturing costs.
- Asset Impairments: The company recognized $5.2 million in impairment charges related to its Hopewell, New Jersey laboratory space and associated equipment due to changes in operational strategy and subleasing activities.
- Capital Raise: In March 2024, the company raised $8.7 million in net proceeds through its At-The-Market (ATM) facility.
Guidance, Outlook, and Risks
Clinical Outlook
- PBFT02 (FTD-GRN): The company reported positive interim biomarker data from the upliFT-D Phase 1/2 trial. Dose 1 resulted in robust, durable increases in CSF progranulin levels and a 13% decrease in plasma neurofilament light chain (NfL) at 12 months. The company plans to evaluate a lower Dose 2 in subsequent patients.
- Expansion: Dosing for FTD-C9orf72 patients is expected to begin in the first half of 2025. Regulatory feedback on registrational trial design is targeted for the first half of 2026.
Liquidity and Capital Resources
As of December 31, 2024, the company held $76.8 million in cash and marketable securities. Management expects these resources to fund operations into the first quarter of 2027. The company anticipates continuing to incur significant losses and will require additional capital to advance clinical trials and commercialization efforts.
Key Risks and Contingencies
- Nasdaq Listing Compliance: The company's stock price fell below the $1.00 minimum bid price requirement. It transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market in January 2025 and is seeking a reverse stock split to regain compliance. Failure to do so could result in delisting.
- Restructuring: In January 2025, the board approved a restructuring plan to reduce the workforce by approximately 55% and cease lab operations in Hopewell, NJ. Estimated severance costs are $1.7 million, with additional impairment charges of $1.0–$3.0 million expected in Q1 2025.
- Legal Proceedings: A former employee lawsuit regarding a 2020 settlement agreement resulted in a judgment in the company's favor in December 2024, though the plaintiff has appealed.
- Profitability: The company has a history of operating losses and does not expect to achieve profitability for the foreseeable future.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $76.8 million cash balance against the projected burn rate, considering the upcoming Q1 2025 restructuring costs and potential delays in clinical milestones.
- Revenue Recognition: Monitor the $8.2 million in deferred revenue from the Gemma out-license to determine when and if it will be recognized as revenue.
- Stock Listing Status: Track the progress of the proposed reverse stock split and the company's ability to maintain the $1.00 minimum bid price on the Nasdaq Capital Market.
- Clinical Data: Await the release of 12-month follow-up data for Dose 1 and interim data for Dose 2 in the second half of 2025 to validate the safety and efficacy profile of PBFT02.
- Restructuring Execution: Confirm the completion of the 55% workforce reduction and the subleasing of the Hopewell laboratory space to mitigate ongoing lease obligations.